Last reviewed · How we verify

NCT01435993

Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis

Terminated Phase 1 Last updated 24 November 2020
What this trial tests

Phase 1 trial testing GSK1223249 in Multiple Sclerosis, Relapsing-Remitting in 3 participants. Terminated before completion.

Timeline
8 September 2011
Primary endpoint
23 January 2012
23 January 2012

Quick facts

Lead sponsorGlaxoSmithKline
PhasePhase 1
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment3
Start date8 September 2011
Primary completion23 January 2012
Estimated completion23 January 2012
Sites2 locations across Italy, Norway

Drugs / interventions tested

Conditions studied

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 60, any sex, with Multiple Sclerosis, Relapsing-Remitting. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate an experimental new drug, GSK1223249 in patients diagnosed with relapsing forms of multiple sclerosis. The study will specifically investigate safety (vital signs like heart rate, blood pressure, Magnetic Resonance Imaging (MRI), and other markers of health from blood samples), tolerability (any side effects that occur, if any), and pharmacokinetics (how the body processes the drug and how long the drug stays in the blood, and in cerebro-spinal fluid). The study will also investigate if patients' own immune system interacts with GSK1223249.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. The Molecular Basis for Remyelination Failure in Multiple Sclerosis.
    Gruchot J, Weyers V, Göttle P, Förster M, et al · · 2019 · cited 79× · PMID 31382620 · DOI 10.3390/cells8080825
  2. A Novel Role of Nogo Proteins: Regulating Macrophages in Inflammatory Disease.
    Zhang N, Cui Y, Li Y, Mi Y. · · 2022 · cited 23× · PMID 34224050 · DOI 10.1007/s10571-021-01124-0
  3. Mechanotransduction: Exploring New Therapeutic Avenues in Central Nervous System Pathology.
    Rocha DN, Carvalho ED, Relvas JB, Oliveira MJ, et al · · 2022 · cited 21× · PMID 35573316 · DOI 10.3389/fnins.2022.861613
  4. Breaking the barriers to remyelination in multiple sclerosis.
    Gharagozloo M, Bannon R, Calabresi PA. · · 2022 · cited 19× · PMID 35255453 · DOI 10.1016/j.coph.2022.102194
  5. An unmet clinical need: roads to remyelination in MS.
    Göttle P, Förster M, Weyers V, Küry P, et al · · 2019 · cited 19× · PMID 33324887 · DOI 10.1186/s42466-019-0026-0
  6. Nogo-A and LINGO-1: Two Important Targets for Remyelination and Regeneration.
    Kalafatakis I, Papagianni F, Theodorakis K, Karagogeos D. · · 2023 · cited 15× · PMID 36901909 · DOI 10.3390/ijms24054479
  7. Therapeutics targeting Nogo-A hold promise for stroke restoration.
    Kumar P, Moon LD. · · 2013 · cited 15× · PMID 23394537 · DOI 10.2174/1871527311312020006
  8. Nogo receptor-Fc delivered by haematopoietic cells enhances neurorepair in a multiple sclerosis model.
    Ye S, Theotokis P, Lee JY, Kim MJ, et al · · 2023 · cited 7× · PMID 37091588 · DOI 10.1093/braincomms/fcad108

Verify or expand the search:

Other trials of GSK1223249

Trials testing the same drug.

Other recruiting trials for Multiple Sclerosis, Relapsing-Remitting

Currently open trials in the same condition.

Other GlaxoSmithKline trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01435993.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing